Kamada Company managed by Amir London earned $ 5.2 million in the first quarter

Kamada Company managed by Amir London earned $ 5.2 million in the first quarter of 2020, a 6% increase over the same quarter in 2019.
The company's revenues from manufacturing and marketing the original Glassia drug for the treatment of chronic lung disease, hereditary blacks, and KedRab, which is a prophylactic vaccine after exposure to rabies - grew 24% to $ 25 million due to the almost undisturbed activity of the company's plant in the Corona crisis.
The company has been able to obtain sufficient amounts of plasma from corona patients that have healed in Israel. This supply allowed Kamada to start the production of a human plasma-based antibody to the corona virus
Kamada's revenue from drug distribution grew 24% in the first quarter of 2020 compared to its corresponding quarter in 2019, totaling $ 8 million. Kamada's gross profit grew by only 2% in the first quarter of 2020 compared to its equivalent in 2019, amounting to $ 11 million, which is 34.4% of turnover compared to 41.7% of turnover in 2019.
 Managed by Amir London earned $ 5.2 million in the first quarter of 2020, a 6% increase over the same quarter in 2019.
Kamada's plasma-based drug revenues grew 24% in the first quarter of 2020 compared to the same quarter in 2019, totaling $ 33 million.
The erosion of gross profit is due to a decline in the gross profitability of the company's two lines of business. Gross profitability of Kamda's industrial operations - the original pharmaceuticals Glassia and Kedrab - fell to 41% of turnover in the first quarter of 2020 compared to 48.5% of turnover in 2019 as a result of a decline in Kedrab sales in the original product mix sold in the past quarter compared to their share in parallel -2019.
The gross profitability of distribution operations was down to 13.6% of turnover in the past quarter compared to 20% of turnover in the corresponding quarter of 2019. Kamdeh's operating profit - held by the Fimi Foundation - fell 7% in the first quarter of 2020 compared to the same quarter in 2019, reaching $ 4.9 million, which is 14.6% of turnover compared with 19.4% of parallel turnover in 2019 due to erosion of gross profit and increased expenses Research and development.
Kamada approved the $ 137-132 million revenue forecast by 2020. Kamada CEO Amir London said the company was able to obtain sufficient quantities of Corona Plasma Plasma cured in Israel. Ministry of Health.
Kamada is partnering with Cadrion Biopharmaceuticals to accelerate the development of the human plasma-based antibody to treat coronary disease and expand its distribution in international markets